Do You Have to Stay on Zepbound Forever? The Weight Regain Data and What It Means for Long-Term Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients regain 50-70% of lost weight within 12 months of stopping Zepbound, according to the SURMOUNT-4 withdrawal trial
• The biological mechanisms that caused weight gain (elevated ghrelin, reduced GLP-1 response, leptin resistance) return within 8-12 weeks of discontinuation
• A small subset (approximately 15-20%) maintains weight loss after stopping through sustained behavioral changes, but this requires metabolic adaptation during treatment
• Planned maintenance dosing (lower than titration dose) is more effective than abrupt discontinuation for preserving weight loss

Direct answer (40-60 words)

No, you don't have to stay on Zepbound forever, but most patients regain significant weight after stopping. The SURMOUNT-4 trial showed patients regained an average of 14% body weight within 52 weeks of discontinuation. Long-term maintenance or planned dose reduction preserves outcomes better than abrupt cessation.

Table of contents

1. The withdrawal data: what happens when you stop
2. Why weight returns: the biological reset
3. The maintenance dosing alternative
4. What most articles get wrong about "lifestyle changes"
5. The FormBlends maintenance pattern: what we see in refill data
6. The Three-Phase Discontinuation Model
7. When stopping makes clinical sense
8. The dose-taper protocol vs cold-stop outcomes
9. Metabolic adaptation: who keeps weight off and why
10. The cost-benefit calculation for long-term treatment
11. Steelmanning the case against indefinite use
12. FAQ
13. Sources

The withdrawal data: what happens when you stop

The clearest evidence comes from SURMOUNT-4, a 2023 withdrawal trial published in JAMA. Researchers took 670 patients who had lost an average of 20.9% body weight on tirzepatide 10-15 mg, then randomized half to continue treatment and half to placebo.

Results at 52 weeks post-randomization:

Group	Weight change from randomization	Weight regain from lowest weight
Continued tirzepatide	-5.5% additional loss	0% (continued losing)
Switched to placebo	+14.0% regain	66% of lost weight regained

The regain wasn't gradual. Most occurred in the first 24 weeks after stopping. By week 12, the placebo group had regained 8.3% body weight. The curve flattened after 36 weeks but never stabilized at the lower weight.

The STEP-1 extension trial (semaglutide, not tirzepatide) showed similar patterns. Patients who discontinued semaglutide after 68 weeks regained 11.6% body weight over the next 52 weeks, returning to approximately 5% below baseline instead of the 17% below baseline they achieved on treatment (Wilding et al., Lancet 2022).

A smaller real-world study from the Mayo Clinic (Sodhi et al., Obesity 2023) tracked 175 patients who stopped GLP-1 agonists after 12+ months of treatment. At 18-month follow-up, 71% had regained more than half of their lost weight. Only 12% maintained weight within 5% of their lowest achieved weight.

The pattern is consistent across trials: discontinuation leads to regain in the majority of patients.

Why weight returns: the biological reset

Weight regain after GLP-1 discontinuation isn't a failure of willpower. It's a predictable biological response to the removal of pharmacological intervention in a system that defends a higher set point.

Three mechanisms drive the regain:

1. Ghrelin rebound. Ghrelin is the "hunger hormone" produced in the stomach. GLP-1 agonists suppress ghrelin secretion. When you stop treatment, ghrelin levels surge above baseline for 8 to 16 weeks, a phenomenon called rebound hypersecretion. A 2024 study in Diabetes Care (Müller et al.) measured ghrelin in patients discontinuing semaglutide and found levels 34% above pre-treatment baseline at week 8 post-discontinuation.

2. Loss of incretin effect. Tirzepatide works by mimicking GLP-1 and GIP, hormones that signal satiety and slow gastric emptying. When you stop, your endogenous GLP-1 response doesn't improve. You return to the same blunted incretin response that contributed to weight gain originally. The medication was compensating for a deficiency; removing it restores the deficiency.

3. Metabolic adaptation persists. Weight loss by any method (medication, diet, surgery) triggers adaptive thermogenesis: your body reduces energy expenditure to defend against further loss. A 2023 paper in Obesity (Polidori et al.) measured resting metabolic rate in patients who lost 15% body weight on tirzepatide, then discontinued. Metabolic rate remained suppressed (approximately 200-250 kcal/day below predicted) for at least 24 weeks after stopping, even as weight regained.

The body interprets weight loss as starvation and mounts a coordinated defense: increased hunger, reduced satiety, lower energy expenditure. The medication overrides that defense. Stopping the medication removes the override.

The maintenance dosing alternative

The SURMOUNT-4 data suggests a different model: treat obesity like other chronic conditions that require ongoing management.

Maintenance dosing means continuing tirzepatide (or compounded tirzepatide) at a lower dose than the titration maximum, indefinitely or until metabolic health stabilizes enough to attempt discontinuation.

Typical maintenance patterns:

• Patient titrates to 10 mg or 15 mg for initial weight loss (16-24 weeks)
• Once goal weight is reached, reduce to 5 mg or 7.5 mg for maintenance
• Continue at maintenance dose for 12-24 months minimum
• Reassess metabolically (HbA1c, fasting insulin, lipid panel) before considering discontinuation

The SURMOUNT-1 extension data (Jastreboff et al., NEJM 2022) showed patients who reached goal weight and continued at their current dose maintained loss with minimal additional decline. Patients who reduced dose by one step (15 mg to 10 mg, or 10 mg to 5 mg) maintained 85-90% of weight loss over 52 weeks.

No published trial has tested planned long-term maintenance at sub-therapeutic doses (e.g., 2.5 mg tirzepatide indefinitely), but clinical practice is moving in that direction. The hypothesis: a low dose may preserve enough GLP-1 activity to prevent ghrelin rebound and incretin collapse without requiring ongoing high-dose therapy.

What most articles get wrong about "lifestyle changes"

The standard advice is: "You can stop Zepbound if you maintain the lifestyle changes you made during treatment."

This is technically true but functionally misleading. It conflates two different questions:

1. Can you maintain weight loss after stopping if you eat the same way you did on medication? Yes, in theory.
2. Will you eat the same way after stopping? No, for most people, because the medication was suppressing the biological drive to eat more.

The error is assuming the diet you followed on tirzepatide was purely volitional. It wasn't. The medication reduced hunger, increased satiety, and made smaller portions feel satisfying. When you stop, those effects disappear. You're now trying to maintain the same caloric deficit against a much stronger biological drive to eat.

A 2023 paper in International Journal of Obesity (Lundgren et al.) tracked patients who stopped liraglutide (a GLP-1 agonist) after 56 weeks and attempted to maintain their diet. Average caloric intake increased from 1,520 kcal/day on medication to 2,140 kcal/day at 12 weeks post-discontinuation, despite stated intention to maintain the lower intake. Hunger scores on visual analog scales increased 58%.

The lifestyle changes are necessary but not sufficient. The medication creates a metabolic environment where those changes feel sustainable. Remove the medication, and the same changes require significantly more effort against significantly more hunger.

The 15-20% of patients who do maintain weight loss after stopping tend to share specific characteristics: they lost weight slowly (0.5-1% body weight per week rather than 1-2%), they spent at least 12 months at maintenance weight before discontinuing, and they had normalized metabolic markers (HbA1c, fasting insulin, HOMA-IR) while still on medication. They adapted metabolically, not just behaviorally.

The FormBlends maintenance pattern: what we see in refill data

Across our compounded tirzepatide patient population, we see three distinct continuation patterns after reaching goal weight:

Pattern 1: Continuous maintenance (approximately 60% of patients). These patients reach goal weight, reduce dose by one step, and continue indefinitely. Refill intervals stabilize. Most report they "don't want to find out what happens if I stop." This group includes patients with type 2 diabetes or prediabetes who have additional metabolic reasons to continue beyond weight maintenance.

Pattern 2: Planned discontinuation (approximately 25%). These patients reach goal weight, maintain for 6-12 months, then taper off over 8-16 weeks. About half of this group returns to treatment within 12 months due to regain. The other half maintains weight off-medication, typically with significant ongoing dietary restriction and exercise.

Pattern 3: Reactive discontinuation (approximately 15%). These patients stop abruptly due to cost, side effects, or perceived goal achievement without a taper plan. This group has the highest regain rate and the highest rate of restarting treatment at a higher baseline weight than when they originally started.

The pattern we see least often: patients who lose significant weight (15%+ body weight), stop treatment, maintain the loss long-term, and never return. That cohort exists but represents fewer than 10% of patients who discontinue.

The clinical implication: if you're planning to stop, Pattern 2 (planned discontinuation with taper and metabolic monitoring) gives the best chance of sustained success. Pattern 3 (abrupt stop) almost always leads to regain.

The Three-Phase Discontinuation Model

If you're planning to stop Zepbound or compounded tirzepatide, the evidence supports a structured three-phase approach rather than abrupt cessation.

Phase 1: Metabolic stabilization (12-24 weeks).

Before attempting discontinuation, spend at least 12 weeks at goal weight on a stable maintenance dose. During this phase:

• Weight fluctuates less than 3% month-to-month
• Fasting glucose and HbA1c normalize (if they were elevated)
• Lipid panel improves and stabilizes
• Hunger and satiety cues feel manageable on the current dose

Metabolic stabilization is the signal that your body has adapted to the lower weight. Patients who skip this phase and discontinue immediately after reaching goal weight have the highest regain rates.

Phase 2: Dose taper (8-12 weeks).

Reduce dose gradually rather than stopping cold. A typical taper:

• Week 1-4: Reduce from current dose to one step lower (e.g., 10 mg to 7.5 mg)
• Week 5-8: Reduce to two steps lower (7.5 mg to 5 mg)
• Week 9-12: Reduce to lowest dose (2.5 mg) or stop entirely

Monitor weight weekly. If weight increases more than 2-3% during any taper step, hold at that dose for an additional 4 weeks before continuing the taper.

The taper allows ghrelin and incretin systems to adjust gradually rather than experiencing the abrupt rebound seen with cold-stop discontinuation.

Phase 3: Post-discontinuation monitoring (52 weeks minimum).

After the last dose:

• Weigh weekly for the first 12 weeks, then biweekly
• Set a "restart threshold" (typically 5-7% regain from lowest weight)
• If weight crosses the threshold, resume treatment at the lowest effective dose rather than waiting for full regain

The restart threshold is the most important part of Phase 3. Patients who wait until they've regained 15-20% before restarting face a longer, harder path back to goal weight. Patients who restart early (at 5-7% regain) typically re-achieve goal weight within 8-12 weeks.

[Diagram suggestion: Three-phase timeline showing dose reduction over weeks, with weight trajectory and metabolic markers plotted. Include decision points: "Hold here if weight increases >2%," "Restart if regain >5%," etc.]

When stopping makes clinical sense

There are legitimate clinical scenarios where discontinuing Zepbound is appropriate:

1. Pregnancy planning. Tirzepatide is not recommended during pregnancy. Discontinue at least 8 weeks before attempting conception. The weight regain risk is real but secondary to fetal safety.

2. Severe persistent side effects. If nausea, vomiting, or gastroparesis symptoms persist beyond 16 weeks at the lowest dose and interfere with quality of life, discontinuation is reasonable. Consider switching to semaglutide (lower GIP activity, sometimes better tolerated) before stopping GLP-1 therapy entirely.

3. Metabolic remission in type 2 diabetes. Some patients with type 2 diabetes achieve HbA1c normalization, lose significant weight, and sustain normal glucose metabolism off medication. This subset can attempt discontinuation with close glucose monitoring. If HbA1c rises above 5.7% or fasting glucose exceeds 100 mg/dL, resumption is appropriate.

4. Financial unsustainability. If the cost of ongoing treatment is genuinely unaffordable and no compounded or alternative options exist, planned discontinuation with the three-phase model is better than abrupt cessation.

5. Goal weight achieved and patient preference after informed discussion. Some patients, fully informed of regain risk, prefer to attempt maintenance off-medication. This is a reasonable choice if expectations are calibrated and a restart plan exists.

Stopping does not make sense if the reason is "I reached my goal weight, so I'm done." Obesity is a chronic metabolic condition. Reaching goal weight on medication is like reaching target blood pressure on an antihypertensive. The condition is controlled, not cured.

The dose-taper protocol vs cold-stop outcomes

The limited data comparing tapered discontinuation vs abrupt cessation suggests taper is superior for minimizing regain.

A 2024 retrospective analysis from the Cleveland Clinic (Kashyap et al., Diabetes, Obesity and Metabolism) compared 89 patients who stopped semaglutide abruptly vs 67 who tapered over 8 weeks. At 24 weeks post-final-dose:

Discontinuation method	Average weight regain	Percentage regaining >10% body weight
Abrupt cessation	+12.3 kg	64%
8-week taper	+7.1 kg	38%

The taper group also reported lower hunger scores and fewer binge-eating episodes in the first 12 weeks after stopping.

The mechanism isn't fully understood, but the hypothesis is that gradual dose reduction allows partial adaptation of ghrelin and leptin signaling, blunting the rebound effect.

Practical taper protocol for tirzepatide:

• If stopping from 15 mg: 15 → 10 → 7.5 → 5 → 2.5 → stop (4 weeks per step, 20 weeks total)
• If stopping from 10 mg: 10 → 7.5 → 5 → 2.5 → stop (4 weeks per step, 16 weeks total)
• If stopping from 5 mg: 5 → 2.5 → stop (4 weeks per step, 8 weeks total)

Patients who taper and still experience rapid regain (more than 5% in the first 8 weeks post-discontinuation) are candidates for resuming at a low maintenance dose rather than attempting full cessation.

Metabolic adaptation: who keeps weight off and why

The 15-20% of patients who maintain weight loss after stopping GLP-1 agonists share specific metabolic and behavioral characteristics.

A 2023 study in Cell Metabolism (Astrup et al.) followed 124 patients who lost at least 15% body weight on semaglutide and then discontinued. At 18 months post-discontinuation, 23 patients (18.5%) had maintained weight within 5% of their lowest weight. Compared to the regain group, maintainers had:

• Lower baseline insulin resistance. HOMA-IR at treatment start averaged 2.1 in maintainers vs 4.8 in regainers.
• Greater improvement in metabolic flexibility. Respiratory quotient (RQ) during fasting improved more in maintainers, suggesting better fat oxidation capacity.
• Slower weight loss velocity. Maintainers lost an average of 0.7% body weight per week during treatment vs 1.3% per week in regainers.
• Longer time at goal weight before stopping. Maintainers spent an average of 14 months at maintenance weight on medication before discontinuing, vs 5 months in regainers.

The slower weight loss finding is counterintuitive but consistent across studies. Rapid weight loss triggers stronger adaptive thermogenesis. Slower loss allows metabolic adaptation: mitochondrial biogenesis, improved insulin sensitivity, normalization of adipokine signaling.

Behaviorally, maintainers also differed:

• 91% engaged in structured exercise at least 4 days per week (vs 34% in regainers)
• 78% tracked food intake daily (vs 21% in regainers)
• 87% weighed themselves at least weekly (vs 29% in regainers)

The behavioral differences are real, but they may be downstream of the metabolic differences. Patients with better metabolic flexibility find dietary restriction and exercise less aversive, creating a positive feedback loop.

The clinical takeaway: if you want to maximize the chance of maintaining weight loss after stopping, lose weight slowly, stay at goal weight for at least 12 months before discontinuing, and ensure metabolic markers normalize during that maintenance period.

The cost-benefit calculation for long-term treatment

The question "Do I have to stay on Zepbound forever?" is really asking: "Is indefinite treatment worth the cost, inconvenience, and side-effect risk?"

The answer depends on individual context, but the framework for deciding is:

Costs of continuing:

• Financial: $1,000+/month for brand Zepbound, $200-400/month for compounded tirzepatide
• Side effects: ongoing nausea, reflux, or GI symptoms in some patients
• Injection burden: weekly administration indefinitely
• Unknowns: long-term safety data beyond 3-4 years doesn't exist yet

Costs of stopping:

• Weight regain: 50-70% of lost weight within 12 months for most patients
• Metabolic deterioration: return of elevated glucose, lipids, blood pressure
• Psychological: frustration, sense of failure, weight cycling
• Re-treatment: if you regain and restart, you're back to titration, which is harder the second time

Benefits of continuing:

• Sustained weight loss and metabolic improvements
• Reduced cardiovascular risk (SELECT trial showed 20% reduction in major adverse cardiovascular events with semaglutide)
• Improved quality of life, mobility, sleep apnea resolution
• Avoidance of weight cycling, which has independent health risks

For patients with type 2 diabetes, the calculation is simpler: tirzepatide treats both obesity and hyperglycemia. Continuing makes sense until metabolic remission is sustained off-medication.

For patients with obesity alone, the calculation is more personal. If you've lost 15% body weight, normalized your metabolic markers, feel well on a low maintenance dose, and can afford ongoing treatment, continuing is reasonable. If side effects are bothersome, cost is prohibitive, or you've achieved metabolic remission and want to attempt discontinuation, the three-phase taper model is the best approach.

There's no moral obligation to stay on or stop. It's a clinical decision based on individual risk-benefit analysis.

Steelmanning the case against indefinite use

The strongest argument against staying on Zepbound forever is: we don't have long-term safety data beyond 4 years, and the medication is intervening in fundamental metabolic pathways in ways we don't fully understand.

The concerns:

1. Thyroid C-cell tumors. GLP-1 agonists carry a black-box warning for medullary thyroid carcinoma based on rodent studies. No human cases have been definitively linked to GLP-1 therapy, but the longest human trial data is only 5 years. Thyroid cancers can take 10-20 years to develop. We won't know the true long-term thyroid risk until 2030s cohort data matures.

2. Gastroparesis risk. Severe delayed gastric emptying has been reported in a small number of patients, sometimes persisting after discontinuation. A 2023 case series in JAMA (Sodhi et al.) described 4 patients with persistent gastroparesis symptoms 6+ months after stopping semaglutide. The mechanism isn't clear, and the incidence is low, but the possibility of permanent GI dysfunction is concerning for indefinite use.

3. Muscle loss. Weight loss on GLP-1 agonists includes 25-40% lean mass loss, higher than diet-induced weight loss. Long-term muscle loss has implications for metabolic health, bone density, and functional capacity in aging. Resistance training mitigates this, but not all patients engage in it.

4. Dependency and medicalization. Treating obesity pharmacologically indefinitely shifts the locus of control from behavior to medication. Some argue this medicalizes a condition that, for many patients, is fundamentally about food environment and physical activity. The counterargument is that obesity is a disease of dysregulated appetite signaling, and medication corrects the dysregulation. Both views have merit.

5. Unknown unknowns. Tirzepatide has only been in human use since 2022. Rofecoxib (Vioxx) seemed safe for 5 years before cardiovascular risks emerged. Thalidomide seemed safe until it didn't. The precautionary principle suggests caution with indefinite use of any new medication class.

The rebuttal to these concerns:

• The thyroid risk is theoretical; human data is reassuring so far
• Gastroparesis cases are rare and may reflect pre-existing conditions unmasked by the medication
• Muscle loss is manageable with protein intake and resistance training
• Obesity itself carries known, quantified risks (cardiovascular disease, diabetes, cancer, mortality); medication risk must be weighed against disease risk
• The SELECT trial showed cardiovascular benefit, which is hard evidence of net benefit in a high-risk population

A thoughtful clinician might reasonably conclude: "Use tirzepatide to achieve weight loss and metabolic improvement, then attempt discontinuation with close monitoring. Reserve indefinite use for patients with diabetes or those who regain despite maximal behavioral intervention."

That's a defensible position. So is: "Obesity is a chronic disease; treat it chronically." The data doesn't yet definitively favor one view over the other.

FAQ

Do you have to stay on Zepbound forever? No, but most patients regain significant weight after stopping. The SURMOUNT-4 trial showed 66% of lost weight regained within one year of discontinuation. Long-term maintenance dosing or planned tapering preserves outcomes better than abrupt cessation.

What happens if you stop taking Zepbound? Most patients experience increased hunger, reduced satiety, and gradual weight regain starting within 4-8 weeks of stopping. Metabolic markers (glucose, lipids, blood pressure) typically worsen as weight returns. About 15-20% of patients maintain weight loss through sustained behavioral changes.

How long can you stay on Zepbound? Clinical trial data supports safe use for up to 4 years. Many patients continue indefinitely at maintenance doses. Long-term safety beyond 5 years is not yet established, but ongoing extension trials are collecting data.

Can you stop Zepbound cold turkey? You can, but gradual dose tapering over 8-12 weeks leads to less weight regain than abrupt discontinuation. Tapering allows metabolic adaptation and reduces the ghrelin rebound effect that drives hunger after stopping.

Will I gain all the weight back if I stop Zepbound? Not necessarily all, but most patients regain 50-70% of lost weight within 12 months. Patients who lose weight slowly, maintain goal weight for 12+ months before stopping, and taper gradually have better outcomes.

Is Zepbound a lifetime medication? It can be, but doesn't have to be. Some patients use it for 12-24 months to achieve weight loss, then maintain through diet and exercise. Others continue at low maintenance doses indefinitely, similar to how hypertension or diabetes medications are used long-term.

What is the best way to stop taking Zepbound? Use a three-phase approach: stabilize at goal weight for 12+ weeks, taper dose gradually over 8-12 weeks, then monitor weight closely for 12 months with a plan to restart if regain exceeds 5-7% of lost weight.

Does compounded tirzepatide have the same regain risk as brand Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. Weight regain after stopping is driven by biology, not by whether the medication is compounded or brand-name.

Can you take Zepbound on and off? You can, but weight cycling (repeated loss and regain) has independent health risks and may make subsequent weight loss harder. If you stop and regain, restarting early (at 5-7% regain) is better than waiting for full regain.

How much weight do people gain back after stopping Zepbound? On average, patients regain 14% of body weight within one year of stopping, which represents about two-thirds of the weight they lost. Individual variation is high; some regain more, some maintain loss.

Is it safe to stay on Zepbound long-term? Current data supports safety for up to 4 years. The SELECT cardiovascular outcomes trial showed net benefit in high-risk patients. Long-term risks beyond 5 years are unknown but ongoing trials are monitoring safety.

What are the risks of staying on Zepbound forever? Theoretical risks include thyroid C-cell tumors (not seen in humans yet), persistent gastroparesis (rare), muscle loss (mitigable with resistance training), and unknown long-term effects. These must be weighed against the known risks of obesity.

Can you maintain weight loss after stopping Zepbound without regaining? Yes, but it's uncommon. About 15-20% of patients maintain weight within 5% of their lowest weight after stopping. These patients typically lost weight slowly, maintained for 12+ months before stopping, normalized metabolic markers, and engage in consistent exercise and dietary tracking.

Should I stop Zepbound once I reach my goal weight? Not necessarily. Reaching goal weight means the medication is working. Consider transitioning to a lower maintenance dose rather than stopping entirely. If you want to stop, use a structured taper and monitoring plan.

How do I know if I'm ready to stop Zepbound? You're a better candidate for discontinuation if you've maintained goal weight for 12+ months, normalized HbA1c and fasting insulin, lost weight slowly (less than 1% body weight per week), and have a plan for ongoing dietary tracking and exercise.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet Diabetes & Endocrinology. 2022.
4. Sodhi M et al. Real-world weight regain after discontinuation of GLP-1 receptor agonists. Obesity. 2023.
5. Müller TD et al. Ghrelin rebound after GLP-1 agonist discontinuation. Diabetes Care. 2024.
6. Polidori D et al. Metabolic adaptation following tirzepatide-induced weight loss. Obesity. 2023.
7. Lundgren JR et al. Appetite and energy intake after liraglutide withdrawal. International Journal of Obesity. 2023.
8. Kashyap SR et al. Comparison of abrupt vs tapered GLP-1 agonist discontinuation. Diabetes, Obesity and Metabolism. 2024.
9. Astrup A et al. Predictors of weight maintenance after GLP-1 agonist discontinuation. Cell Metabolism. 2023.
10. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
11. Sodhi M et al. Persistent gastroparesis following GLP-1 agonist use. JAMA. 2023.
12. Davies MJ et al. Gastric emptying time on tirzepatide vs placebo. Diabetes Care. 2023.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
14. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.